Inion explores BMP-4 product for preventing abnormal bone growth:
This article was originally published in Clinica
Executive Summary
Finnish orthopaedics firm Inion has received a patent in Finland covering a genetically modified form of the bone morphogenetic protein BMP-4 that could prevent the abnormal formation of bone in non-bony tissues, a condition known as heterotopic ossification (HO). HO is observed in up to 50% of patients undergoing spinal fusion surgery and in 71% of those receiving total hip replacements, said the Tampere firm. The company, which has also had a US patent issued for its BMP-4 technology, said it is exploring routes to market the product, which may involve an out-licensing deal to commercialise the intellectual property with a partner. There is significant market potential for a product that reduces the incidence of HO in a more cost-effective form, said the firm.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.